Detalhe da pesquisa
1.
SuFEx-based chemical diversification for the systematic discovery of CRBN molecular glues.
Bioorg Med Chem;
104: 117699, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38608634
2.
Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M4 muscarinic acetylcholine receptor.
Bioorg Med Chem Lett;
56: 128479, 2022 01 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34838649
3.
Chemical tools to expand the ligandable proteome: diversity-oriented synthesis-based photoreactive stereoprobes.
bioRxiv;
2024 Feb 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38464067
4.
Enniatin A Analogues as Novel Hsp90 Inhibitors that Modulate Triple-Negative Breast Cancer.
ACS Med Chem Lett;
14(12): 1785-1790, 2023 Dec 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38116437
5.
Development of VU6019650: A Potent, Highly Selective, and Systemically Active Orthosteric Antagonist of the M5 Muscarinic Acetylcholine Receptor for the Treatment of Opioid Use Disorder.
J Med Chem;
65(8): 6273-6286, 2022 04 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35417155
6.
Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist.
ACS Med Chem Lett;
12(8): 1342-1349, 2021 Aug 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34413964
7.
Old and New Approaches to Target the Hsp90 Chaperone.
Curr Cancer Drug Targets;
20(4): 253-270, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31793427